Cyclophosphamide for myasthenia gravis: a comeback?

COI Statement

Competing interests: CBT has served as a member of the advisory board for argenx, Alexion, UCB and Janssen. She has been a consultant for argenx, Janssen and UCB. She has received research support from US Department of Defense, Muscular Dystrophy Canada and MGNet. Grifols and Octapharma. She is the primary developer of the MGII and may receive royalties. HDK: Consultancy or Research Support: Grifols, CSL Behring, Octapharma, Takaeda, Pfizer, Biogen, Akcea, Alexion, Terumo, UCB, Roche, Argenx, Dyne, Merz, Syneos.